1、April 2025 2024 Deal-making Roundup An in-depth analysis of 2024s global deal-making trends.This report unpacks the years biggest moves,top therapeutic areas,and standout transactions as tracked by Biomedtracker.2April 2025 Copyright 2025 Evaluate,a Norstella company.(Unauthorized photocopying prohi

2、bited.)IntroductionDuring 2024,the biopharma industry achieved a total potential deal value(PDV)of$191.9 billion across 690 alliances.Although deal volume for alliances decreased by 28 transactions from 2023,the overall aggregate value was$5 billion more and the average deal value(among deals with d

3、isclosed values)was$671 million,an increase of 4%over 2023s average PDV.Oncology was the most active therapeutic area for partnering.On the other hand,the 2024 biopharma merger and acquisition dollar value of$79.4 billion reached only about half of the 2023 total,yet 2024 deal volume showed a slight

4、 increase over the previous year,with 140 deals.Four$10 billion-plus deals completed in 2023(together valued at close to$80 billion)greatly inflated the 2023 total dollars;if we remove those outliers,the 2024 total PDV is more in line with the 2023 PDV.Biopharma financing,which brought in an aggrega

5、te$88.6 billion from 1,056 deals,saw a 13%rise in the number of transactions as well as a 19%increase in deal value over 2023s totals.The 2024 average deal value of$83.9 million was also up by 6%compared to 2023.In the medtech industry,financing activity in 2024 also ramped up in both dollar value a

6、nd deal volume($14.8 billion for 350 deals vs$12.2 billion for 300 deals in 2023).M&A activity was particularly strong,with seven separate billion-dollar-plus acquisitions(the same as 2023),with total 2024 medtech M&A spend at$35.9 billion from 57 deals,a 32%increase in deal value,yet a 31%d